J9317 Sacituzumab govitecan-hziy
J-Codes
Also known as: sacituzumab govitecan, Trodelvy
Injection of sacituzumab govitecan-hziy, an anti-trophoblast cell surface antigen 2 antibody-drug conjugate. Used for triple-negative breast cancer.
Clinical Context
Used for metastatic triple-negative breast cancer. Antibody-drug conjugate targeting trophoblast cell surface antigen 2 with camptothecin payload.
RVU Breakdown
| Work RVU | 0.00 |
| Practice Expense RVU | 0.00 |
| Malpractice RVU | 0.00 |
| Total RVU | 0.00 |
Specialties
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.